Journal article
Charting the Course of Targeted α Therapy With First-in-Human, Postadministration Image-Guided Dosimetry and Response Assessment of 212Pb-VMT-α-NET in Metastatic Neuroendocrine Tumors
Clinical nuclear medicine, Vol.49(6), pp.546-548
06/2024
DOI: 10.1097/RLU.0000000000005190
PMID: 38537249
Abstract
212Pb emerges as a compelling in vivo α-particle generator for targeted α therapy due to its favorable half-life (t1/2 = 10.6 hours) aligning with the biological half-lives of small peptides and its potent α-particle emissions within the decay series. However, one of the challenges with 212Pb is to perform appropriate image-guided dosimetry. To date, all the data have been extrapolated from its imaging analog, 203Pb. We present the first-in-human posttherapy image-guided dosimetric estimates of a single cycle of 212Pb VMT-α-peptide, administered in a 41-year-old woman with an advanced grade 2 NET. The patient also demonstrated partial response on treatment.
Details
- Title: Subtitle
- Charting the Course of Targeted α Therapy With First-in-Human, Postadministration Image-Guided Dosimetry and Response Assessment of 212Pb-VMT-α-NET in Metastatic Neuroendocrine Tumors
- Creators
- Navneet Singh - Fortis Memorial Research InstituteNishant Rana - Fortis Memorial Research InstituteParul Thakral - Fortis Memorial Research InstituteDharmender Malik - Fortis Memorial Research InstituteMichael K Schultz - Perspective Therapeutics, Inc, Coralville, IAIshita B Sen - Fortis Memorial Research Institute
- Resource Type
- Journal article
- Publication Details
- Clinical nuclear medicine, Vol.49(6), pp.546-548
- DOI
- 10.1097/RLU.0000000000005190
- PMID
- 38537249
- NLM abbreviation
- Clin Nucl Med
- eISSN
- 1536-0229
- Language
- English
- Electronic publication date
- 03/28/2024
- Date published
- 06/2024
- Academic Unit
- Radiology; Radiation Oncology
- Record Identifier
- 9984577109002771
Metrics
8 Record Views